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Abstract
Pharmacological cognitive enhancers (PCEs) are used to improve cognitive functions, such as attention,
learning, memory and planning in patients with impairments in cognition resulting from traumatic brain
injury (TBI) or from neuropsychiatric disorders such as Alzheimer’s disease (AD), mild cognitive
impairment, schizophrenia, and attention deﬁcit hyperactivity disorder (ADHD). Moreover, PCEs have
been shown to improve cognition in healthy volunteers with no psychiatric disorders. This article
describes the rationale behind the need for their use in neuropsychiatric patients and illustrates how PCEs
can ameliorate cognitive impairments, improve quality of life and wellbeing, and therefore reduce the
economic burden associated with these disorders. We also describe evidence that PCEs are being used as
cognitive enhancers by healthy people. Crucially, as the lifestyle use of these drugs becomes very popular
in the healthy population, a ﬁnal aim is to present an overview of the current and future neuroethical
considerations of enhancing the healthy brain. As information regarding their actual use, beneﬁts and
harms in various healthy populations is currently lacking, we propose research that aims to obtain
relevant empirical data, monitor the short- and long-term eﬀectiveness and side-eﬀects, and initiate
accurate surveys to determine current patterns and quantity of usage of PCE drugs by healthy people.
Furthermore, in order to instigate a dialogue between neuroethics and neuropsychopharmacology, we
urge scientists to explore and communicate the social and ethical implications of their research to the
public. Finally, we discuss and highlight other means of enhancing cognition in both patients and healthy
adults, including education and physical exercise.
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Pharmacological cognitive enhancers (PCEs)
Cognitive impairment is a core deﬁcit of a number of
neuropsychiatric disorders (Goldberg & Green, 2002;
Weickert et al. 2000) and drugs that improve facets of
cognition such as attention, learning, memory and
executive functions are known as PCEs (Morein-Zamir
et al. 2008; Sahakian & Morein-Zamir, 2010). These
drugs alter neurotransmitter modulation of cognition
leading to improvements in cognitive deﬁcits in
patients with traumatic brain injury (TBI) (Teitelman,
2001), depression (Vaishnavi et al. 2006), addiction
(Shearer & Rodgers, 2009), multiple sclerosis (Kraft &
Bowen, 2005; Zifko et al. 2002), Parkinson’s disease
(Nieves & Lang, 2002), and those suﬀering from
Alzheimer’s disease (AD), schizophrenia, and atten-
tion deﬁcit hyperactivity disorder (ADHD). The goal
for their use is to ameliorate impaired functional out-
comes. There is substantial opportunity for meeting
the challenge of improving cognition and mental
wellbeing in those with mental health problems and
for reducing substantially the factors that contribute
to the loss of mental, social and economic capital
(Beddington et al. 2008).
A good illustration is AD, which is a neurodegener-
ative disorder characterized by a decline in cognitive
and behavioural functioning. It is the commonest
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REVIEWcause of dementia and one of the most disabling and
burdensome health conditions worldwide (Ferri et al.
2005). There are currently 820 000 people with de-
mentia in the UK, which costs £23 billion per year
(Alzheimer’s Society, 2007). Globally, if no eﬀective
prevention strategies or neuroprotective medications
are developed, 81.1 million people will suﬀer from
dementia by 2040 (Ferri et al. 2005). However, a treat-
ment that would reduce severe cognitive impairment
in older people by just 1% a year would cancel out all
estimated increases in the long-term care costs due to
ageing population (Comas-Herrera et al. 2007).
Cognitive enhancers hold signiﬁcant beneﬁts in
ameliorating these cognitive impairments in AD
and countering these economic and social burdens
(Alzheimer’s Research Trust, 2010; Kaduszkiewicz
et al. 2005). For example, cholinesterase inhibitors
(ChEI), such as donepezil, that inhibit centrally active
acetylcholinesterase (AchE) and boost acetylcholine in
the brain, compensate for the degeneration of neurons
in the neocortex that regulate attention and memory
(Stahl, 2009), and are eﬀective in the treatment of mild
and moderate AD (Eagger et al. 1991a,b; NICE, 2010).
Selective ChEIs release growth factors, interfere
with amyloid deposition, or modulate nicotinic re-
ceptors (Pepeu & Giovannini, 2009; Stahl, 2009) while
future drugs may exert their beneﬁcial eﬀects by acti-
vating various neurotransmitters including nora-
drenaline (NA), dopamine (DA), serotonin (5-HT),
GABA and glutamate (Keowkase et al. 2010). Further-
more, drugs that activate synaptic NMDA receptors
work synergistically with AMPA receptors to produce
long-lasting changes in the synaptic functioning and
enable the encoding of new memories. This promotes
the phosphorylation of CREB that slows down the
pathological changes observed in AD (Snyder et al.
2005). However, these drugs only minimize the neural
damage caused by glutamate’s neurotoxic eﬀects and
evidence is needed of improved episodic memory
in AD patients. Importantly, some drugs have signiﬁ-
cant side-eﬀects. For example, donepezil is contra-
indicated for people with liver problems (Mount &
Downton, 2006) while others have modest clinical ef-
ﬁcacy in early (Lanctot et al. 2003) and advanced stages
(Alzheimer’s Association, 2005). Furthermore, about
30–40% of patients with AD may not respond to ChEI,
and approximately 29% of patients treated with ChEI
leave clinical trials because of adverse events (Birks,
2006). Therefore, it is important to develop novel and
eﬀective neuroprotective agents that selectively target
the underlying neuropathology associated with am-
nestic mild cognitive impairment and AD. Developing
these drugs could be advantageous to the individual
and to society, particularly given the signiﬁcant ageing
population in the UK and the USA. It is not within the
scope of this review to cover in detail the range and
action of all the current and novel PCEs and therefore
the reader is referred to Stahl (2009) and The Academy
of Medical Sciences (2008).
Notwithstanding, PCEs might also improve the
quality of life in patients with TBI, which is the most
common cause of disability in young people
(Colantonio et al. 2010; Norup et al. 2010). For example,
survivors of TBI often suﬀer from chronic cognitive
deﬁcits (Salmond et al. 2005, 2006) in areas such as
sustained attention and learning which implicate im-
paired cholinergic function (Polo et al. 2002; Salmond
& Sahakian, 2005). Furthermore, voxel-based mor-
phometry studies reveal structurally reduced grey-
matter density and changes in hippocampus and
neocortex in TBI patients. This is further consistent
with the cholinergic dysfunction account that com-
monly contributes to the development of TBI-induced
cognitive impairments (Salmond et al. 2005). Con-
sequently, the use of ChEIs that increase cholinergic
function may be of beneﬁt to TBI patients (Tenovuo
et al. 2009). However, whether PCEs improve apathy,
which is often considerably disabling and detrimental
to rehabilitative eﬀorts in TBI patients, needs to
be determined in future research (Keenan et al. 2005;
Padala et al. 2007).
Equally,patientswithschizophreniacanalsobeneﬁt
from PCEs through improvements in executive func-
tions (Barnett et al. 2010). Schizophrenia is a complex,
lifelong disorder that signiﬁcantly impairs cognitive
and motivational function in approximately 1% of the
world’s population. Although psychotic symptoms,
such as hallucinations and delusions, can be managed
with antipsychotic treatment (Canuso et al. 2009), pa-
tients continue to suﬀer dysfunctions in cognition, af-
fect and motivation, which account for substantial
decrements in social and occupational functioning
(Harvey et al. 2007; Matza et al. 2006; Velligan et al.
2006). Speciﬁcally, evidence indicates that these
patients are substantially impaired in a wide range of
neuropsychological task performances (Heinrichs &
Zakzanis, 1998; Reichenberg & Harvey, 2007), and
these impairments often impede everyday function
and quality of life for many patients (Morein-Zamir
et al. 2007). PCEs may prove beneﬁcial as an add-on
to antipsychotic medication, as it has been suggested
that, in patients with schizophrenia, even small im-
provements in cognitive functions, such as enhancing
the ability to adapt eﬃciently to new situations and to
plan eﬀectively, could help them make the transition
to independent living (Altamura & Glick, 2010;
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will not only improve their quality of life, but will also
enable them to access jobs and integrate with society.
In consequence, governments are relieved from the
cost burden of ongoing care for these patients (Nicholl
et al. 2010). In keeping with this, we have shown
that PCE drugs improve cognitive performance in
patients with schizophrenia (Barnett et al. 2010), and
that modaﬁnil (Provigil
1), a wake-promoting drug
licensed for narcolepsy, can improve cognitive ﬂexi-
bility as measured by extra-dimensional attentional
set-shifting in patients with chronic schizophrenia
(Turner et al. 2004a). Recently, modaﬁnil has been
shown to enhance some aspects of social cognition
such as emotional facial recognition in patients
with ﬁrst episode of psychosis (Scoriels et al. 2010).
However, many of the studies cited above are acute
proof of concept studies and therefore one must be
cautious about inferred long-term clinical signiﬁcance,
which still requires conﬁrmation in experimental
studies.
Nevertheless, children with ADHD can beneﬁt from
PCEs. ADHD is a heritable and disabling disorder
characterized by core cognitive and behavioural
symptoms of impulsivity, hyperactivity, and inatten-
tion. It is the most prevalent neuropsychiatric child-
hood disorder which aﬀects around 3–7% of children
worldwide (APA, 2000; Polanczyk et al. 2007).
Structural abnormalities in fronto-striato-circuitry
(Durston et al. 2003) and dysfunction in catecholamine
neurotransmission, speciﬁcally in NA and DA path-
ways in the prefrontal cortex (PFC) have been im-
plicated in ADHD (Yang et al. 2007). This leads to
ineﬃcient information processing and hypo-activation
in the frontal lobes (Stahl, 2008). As a result, ADHD
patients have signiﬁcant impairments in performing
working memory (WM) and executive function tasks
(Biederman et al. 2007; Chamberlain et al. 2007;
Dowson et al. 2004). However, if these impairments are
not treated early, they can lead to signiﬁcant negative
life events such as drop out from education, job dis-
missal, criminal activities, substance abuse, and
driving accidents (Barkley, 2006). PCEs such as
methylphenidate (Ritalin
1) (Dodds et al. 2008), selec-
tive NA reuptake inhibitor (SNRI) atomoxetine
(Strattera
1) (Chamberlain et al. 2007; Donnelly et al.
2009) and modaﬁnil (Turner et al. 2003), increase DA
and NA levels in the PFC (Mehta et al. 2004; Stahl,
2009; Wilens, 2006) and alleviate cognitive impair-
ments in ADHD patients (DeVito et al. 2008; Turner
et al. 2004b). Indeed, studies in our laboratory that use
double-blind placebo-controlled designs showed that
methylphenidate improves WM, cognitive ﬂexibility,
attention and response inhibition in both children and
adults with ADHD (DeVito et al. 2008; Turner et al.
2004b). For example, DeVito et al. (2008) used the
Cambridge Gambling Task, a test of decision making
and risk taking, and showed that a single 0.5 mg/kg
dose of methylphenidate reduced large bets on this
task in ADHD boys, who performed similarly to
healthy boys without medication. In consequence,
PCEs can eﬀectively improve core symptoms, abnor-
mal behaviours, self-esteem, cognition, social and
family function in ADHD patients (Sahakian &
Morein-Zamir, 2007). However, methylphenidate is
successful in treating only about 60–70% of ADHD
children, meaning that 30% of patients with ADHD
either do not respond to treatment or the drug causes
adverse side-eﬀects, such as headache, stomach pain,
loss of appetite, trouble sleeping, dizziness and
nausea, which precludes the use of methylphenidate.
Atomoxetine may be a more acceptable treatment due
to its low abuse liability and minimal adverse side-
eﬀects (Heil et al. 2002). Still, unlike methylphenidate
which improves spatial WM (SWM), sustained atten-
tion, and response time in ADHD patients and healthy
volunteers (Elliott et al. 1997; Turner et al. 2004b), ato-
moxetine only improves response inhibition possibly
due to its selective NA modulation (Chamberlain et al.
2006, 2007), and is likely to be less eﬀective in treating
the range of cognitive deﬁcits associated with ADHD.
Therefore, there is a need for medication with im-
proved eﬃcacy and reduced side-eﬀects for ADHD.
Furthermore, studies employing the same method-
ology show that modaﬁnil also signiﬁcantly improves
short-term memory span, visual memory, spatial
planning, and stop-signal motor inhibition in ADHD
adults (Turner et al. 2004b). These improvements are
consistent with randomized, double-blind placebo-
controlled clinical trials with modaﬁnil that demon-
strate symptom reduction in ADHD children and
adolescents(Biederman etal.2005,2006;Greenhilletal.
2006; Swanson et al. 2006). Hence, in psychiatry ethics,
developing novel PCEs that improve the wellbeing
and quality of life for these patients meets the ‘right
to receive eﬀective treatment that would oﬀer them
a reasonable opportunity to improve their mental
condition’ (Bloch & Green, 2008, p. 490).
Pharmacogenomics
Another important argument for developing
novel PCEs relates to the rise of pharmacogenomics
and individualized medicine that aim to combat
neuropsychiatric and neurodegenerative diseases.
Pharmacogenomics is the discipline behind how genes
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growing evidence that key gene variants can
change activity within speciﬁc neuronal circuits and,
as a result, inﬂuence particular cognitive-aﬀective
phenomena. For example, the catecholamine-O-
methyltrasferase (COMT) gene has been shown to af-
fect responses to COMT inhibitors and to predict WM
performance whereas the Val
108/158 polymorphism ex-
erts a signiﬁcant eﬀect on enzyme activity and aﬀects
DA-regulated PFC activity during WM tasks, and also
modiﬁes the eﬀect of dopaminergic drugs (e.g. the
COMT enzyme inhibitor tolcapone) in the PFC (Diaz-
Asper et al. 2008; Goldberg et al. 2003). Similarly, the
therapeutic response in AD appears to be genotype-
speciﬁc, with APOE-4/4 carriers being the worst
responders to conventional treatments (Cacabelos,
2005). However, although behavioural phenotypes
and action of PCEs are generally complex (Diaz-Asper
et al. 2006), both reﬂecting the action of multiple genes
and neurotransmitters respectively, it is possible that
using pharmacogenomics to develop targeted PCEs
for particular subgroups and individual responsive-
ness will lead to greater eﬃcacy and reduced side-
eﬀects.
PCEs improve cognition in healthy individuals
PCEs also improve cognition in non-sleep-deprived
healthy adults. For example, Turner et al. (2003)
showed that a single oral dose of modaﬁnil (100 mg or
200 mg) signiﬁcantly improved performance on tests
of digit span, visual pattern recognition memory,
spatial planning, and stop signal reaction time (SSRT)
task, or response inhibition, in healthy volunteers.
Modaﬁnil also improved the response time in tests of
decision making, delayed matching to sample, and
spatial planning (Mu ¨ller et al. 2004). More recently,
it improved accuracy in an attention-shifting task,
without reaction time trade-oﬀ (Marchant et al. 2009),
especially when participants’ resources were most
challenged. Consistent with this, Mu ¨ller et al. (2004)
demonstrated that modaﬁnil signiﬁcantly reduced
error rates in a long-delay visuo-spatial task and
manipulation conditions, without speed-accuracy
trade-oﬀ.
Similarly, an acute dose of atomoxetine can improve
response inhibition in healthy adults. Chamberlain
et al. (2009) used functional magnetic resonance
imaging and examined the brain mechanism by which
atomoxetine exerts its cognitive enhancing eﬀects
in healthy volunteers. They found that atomoxetine
led to increased activation in the right inferior frontal
gyrus (RIFG) when participants attempted to inhibit
their responses in the SSRT task. The RIFG has pre-
viously been shown to be activated during inhibitory
motor control (Aron et al. 2003). It is thought that ato-
moxetine improves response inhibition via nora-
drenergic mechanisms. In contrast, methylphenidate
has been shown to enhance SWM performance in
healthy adults (Elliott et al. 1997). In a study employing
sophisticated neuropsychological tests and brain-
imaging measures (see Supplementary online ma-
terial),Mehtaetal.(2000)showedthatmethylphenidate
improves both performance and eﬃciency in the SWM
neural network, which includes the dorsolateral PFC
and posterior parietal cortex in healthy volunteers
(Owen et al. 1996). These areas have been signiﬁcantly
associated with WM and executive functions (Robbins
et al. 2000). Moreover, studies using positron emission
tomography and contrasting [
11C]raclopride binding,
with the participants either on or oﬀ methylphenidate,
have further indicated that methylphenidate inﬂu-
ences dopaminergic function, particularly in the stria-
tum (Wang et al. 1999). Other DA agonists improve
WM and performance of executive tasks in healthy
individuals (Mehta & Riedel, 2006; Roesch-Ely et al.
2005). There is evidence for enhancement of other
forms of memory by PCEs. For example, evidence
from healthy volunteers show that ampakine CX516
and ChEIs also lead to moderate improvements in
recall and short-term memory (Wezenberg et al. 2007).
In particular, pilots who took donepezil just before
learning speciﬁc manoeuvres in a ﬂight simulator
outperformed a control group on tests of performance
conducted 1 month later (Yesavage et al. 2002).
However, the mechanism of action for improvement
in attention, memory and executive function of PCEs
still remains to be determined in many cases. For
example, to exert its cognitive enhancing eﬀects,
modaﬁnil has been shown to elevate numerous
neurotransmitters including NA, DA and glutamate
(Minzenberg & Carter, 2008; Volkow et al. 2009).
Neurotransmitter modulation of cognition
Evidently, as these improvements relate to neuro-
transmitter modulation and function (Iversen et al.
2009), the eﬀects of some PCEs might follow the
Yerkes–Dodson law, which explains the relationship
between arousal and performance. This principle
might be translated to several neurotransmitter
systems where cognitive function often follows an
inverted U-shaped curve, with deviations from the
optimal level in either direction producing sub-
optimal performance (Robbins & Sahakian, 1979;
Robinson & Sahakian, 2009). For instance, low levels of
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improve executive function whereas higher levels of
NA release engage a1-adrenergic receptors which
cause signiﬁcant stress in humans and animals
(Arnsten, 2000; Finlay et al. 1995) and impair pre-
frontal functionality (Ramos & Arnsten, 2007).
A similar U-inverted relationship is evidenced be-
tween DA and WM function (Vijayraghavan et al.
2007) as both marked increases and decreases of DA in
the PFC have been associated with sub-optimal per-
formance (Cools et al. 2003; Iversen, 2001, p. 31).
Consistent with this hypothesis, methylphenidate im-
proves cognitive performance in individuals with
greater impairment (Konrad et al. 2004; Mehta et al.
2000) while guanfacine (Tenex
1), an a2-adrenergic
receptor agonist, has beneﬁcial eﬀects on WM and
attentional functions in patients with ADHD, but does
not improve WM or executive functions in healthy
male volunteers (Mu ¨ller et al. 2005). Thus, the eﬀects of
pharmacological substances on cognition are complex
as cognition is a multifaceted construct encompassing
numerous mental functions including both cold cog-
nition (such as attention, planning, problem solving,
and response inhibition) and hot cognition (such as
risky decision making; Roiser et al. 2006). For instance,
PCEs may further modulate important human virtues
such as creativity. A recent study by Farah et al. (2009)
showed that the mixed amphetamine salts, adderall,
licensed for the treatment of ADHD, enhanced per-
formance on convergent tasks of creativity for lower-
performing individuals and either impaired or did not
change it for higher-performing individuals. These
results on improvement and impairment on higher
cognitive function with PCEs raises the issue of what
we mean by a general term ‘enhancement’. As healthy
adults fall into a wide spectrum of normality,
some individuals may be improved by a PCE drug
while others remain unchanged or are even impaired
(Randall et al. 2005; Robbins & Sahakian, 1979).
Furthermore, there is as yet no robust empirical re-
search to demonstrate that PCEs have eﬀects on di-
vergent thinking in healthy people.
Lifestyle use of PCEs by healthy individuals
The above results demonstrate the potential of PCEs to
enhance certain cognitive domains in healthy adults.
Therefore, attitudes towards their use by the general
population need to be considered. In the next section,
we focus our discussion on current and future trends
of the use of PCEs by healthy people.
In the past few years there has been an unpre-
cedented rise in the use of PCEs among healthy
individuals for cognitive enhancement. Cognitive en-
hancement can be deﬁned as the ampliﬁcation or ex-
tension of core capacities of the mind through
improvement or augmentation of internal and external
information processing systems (Bostrom & Roache,
unpublished data). Healthy university students
(Desantis & Hane, 2010) and academics (Sahakian &
Morein-Zamir, 2007) have been using PCEs to
improve their cognitive function. More speciﬁcally,
students are taking PCEs to improve academic per-
formance (Rabiner et al. 2009) and are framing their
actions as both physically harmless and morally ac-
ceptable (Desantis & Hane, 2010). For example, in the
USA, 16% of college students (Babcock & Byrne, 2000)
and 8% of undergraduates reported having illicitly
obtained and used prescription stimulants (Hall et al.
2005; Lord et al. 2009; Teter et al. 2005). Furthermore,
a 2005 survey by the US National Institute on
Drug Abuse (NIDA, 2005) found that 2.5% of 13- to
14-yr-olds, 3.4% of 15- to 16-yr-olds and 5.1% of 17- to
18-yr-olds abused methylphenidate. In 2009, the
ﬁgures for these groups were 1.8%, 3.6% and 2.1%,
respectively (NIDA, 2009). Presumably, these young
people are obtaining stimulant drugs from others who
have prescriptions or purchasing them via the internet
or street dealers.
Currently, the global market share of modaﬁnil is
more than US$700 million per year (Norman & Berger,
2008). Consistent with Greely’s (2006) claim, that
healthy physicians on call, students and academics are
increasingly using PCEs to enhance cognitive abilities,
it is estimated that around 90% of modaﬁnil is pre-
dominantly used oﬀ-label by healthy, non-sleep-
deprived individuals (Baranski et al. 2004; Vastag,
2004). In contrast, beta-blockers that are prescribed to
reduce anxiety in clinical patients have been used by
musicians to dampen physiological tremors in order to
improve their performances on stage (Tindal, 2004).
In the UK, a newspaper survey of 1000 students
showed that 1 in 10 were taking prescription drugs for
cognitive enhancement (Lennard, 2009). In England,
prescription rates of stimulants have been rising
steadily from 220000 in 1998 to 418300 in 2004
(Niyadurupola, 2008). In 2008, the journal Nature con-
ducted a poll about the use of PCEs by healthy aca-
demics, in which 1400 scientists from 60 diﬀerent
countries responded (Maher, 2008). One in ﬁve re-
spondents used drugs for cognitive enhancement,
with 52% of them obtaining the drug by prescription,
while 34% obtained the drug via the internet and 14%
through their pharmacy. The most popular drug was
methylphenidate, with 62% of users; 44% reported
taking modaﬁnil mainly to improve concentration,
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Of all respondents, 96% thought that people with
neuropsychiatric disorders should be given cognitive
enhancing drugs. In contrast, 86% of respondents
thought that healthy children under the age of 16 yr
should be restricted from taking PCE drugs.
Although some of these data were not rigorously
collected, they nonetheless suggest the increased use
of PCEs among healthy individuals. Their widespread
use is not surprising given that small percentage in-
crements in performance can lead to signiﬁcant im-
provements in functional outcome. Indeed, a 10%
improvement in memory score could lead to an im-
provement in an A-level grade or degree class
(Academy of Medical Sciences, 2008, p. 150).
Neuroethical issues in cognitive enhancement
Nevertheless, the increase in lifestyle use of PCEs by
healthy people raises numerous ethical issues that in-
form the growing ﬁeld of neuroethics. Neuroethics is
the study of the ethical, legal and social questions that
arise when scientiﬁc ﬁndings about the brain are
carried into medical practice, legal interpretations and
health and social policy (Marcus, 2002). As such,
modifying our inherent self, character and individu-
ality through PCE drugs has important implications
for society. For these reasons, their lifestyle use has
prompted a signiﬁcant interest both in the media and
the public (Coveney et al. 2009; Stix, 2009). There is a
concern that PCEs will threaten our notion of person-
hood and will dampen essential characteristics of
what it means to be human (Farah et al. 2004;
President’s Council on Bioethics, 2003).
As a consequence, enhancing the brain and higher
cognitive processes demands strong ethical con-
siderations and a practical policy framework. To ad-
dress this, we have argued elsewhere that before PCE
drugs are prescribed to healthy people, their long-
term safety, side-eﬀects and their eﬀectiveness must be
tested to provide important facts necessary for further
decision making about their regulation (Sahakian &
Morein-Zamir, 2010). Moreover, we have engaged
with the media about the need to establish regulations
for the use of PCE drugs by healthy people (Mohamed
& Sahakian, 2010). In Nature, we emphasized the
need to ensure their safe use by healthy people (Greely
et al. 2008) while in Science we advocated that ethical
considerations in regard to societal issues associated
with the use of PCEs by healthy people should be
part of neuroethical training within university
neuroscience programmes (Sahakian & Morein-Zamir,
2009).
But, what are the advantages and disadvantages of
healthy people using PCEs? Since PCEs improve those
with low cognitive performance (Robbins & Sahakian,
1979), it might be possible to mitigate the adverse en-
vironmental eﬀects, such as poverty, on the brain and
cognition through their use. This might contribute to
removing disparity in society. It may also be that
some ‘healthy’ people actually have undiagnosed at-
tentional or other problems and are actually self-
medicating with drugs such as ritalin. Furthermore,
even healthy adults, who normally function well, are
not always performing optimally due to sleep depri-
vation, jet lag or other stressors, and some might need
to perform at their best possible level on every oc-
casion (e.g. surgeons, air traﬃc controllers). In ad-
dition, PCEs might enable us to perform better in other
competitive or life threatening situations. For instance,
psychostimulants have been employed to boost cog-
nition in soldiers in combat (Caldwell et al. 2000;
Moran et al. 2007; Russo et al. 2008). PCEs have
also been demonstrated to improve performance
in shift workers (Ballon & Feifel, 2006), pilots
(Caldwell, 2001) and school pupils with ADHD (Trout
et al. 2007). Recently, the US Defence Advanced
Research Project Agency (DARPA, 2007) introduced
the Augmented Cognition Programme to enhance
soldiers’ memory and cognition through technology
when under conditions of interrupted sleep and
stress. However, if proven to be safe, PCEs may be
preferred for cost-eﬀectiveness when compared to
other methods of enhancement such as expensive
technology.
In contrast, the disadvantages of using PCEs in-
clude the potential harms and long-term side-eﬀects
that they might have in healthy people, particularly in
adolescents where the brain is still in development.
There are strong safety concerns, especially in the ab-
sence of informative data, for healthy individuals as
the risk of adverse side-eﬀects might outweigh the
beneﬁcial eﬀects of PCE drugs. The abuse liability of
some of the PCEs such as methylphenidate is also
a concern. A recent study showed that modaﬁnil
blocked DA transporters and increased DA in the
caudate, putamen and nucleus accumbens in healthy
human brain (Volkow et al. 2009), which are areas in a
network known to be involved in drug-seeking be-
haviour and addiction (Volkow & Li, 2004). This in-
dicates the need for awareness about the risks
involved in PCE use among healthy people and shows
that a full ethical consideration of their use is required.
To date, there have been no randomized psycho-
pharmacological trials investigating the long-term ef-
fects of PCE drugs on healthy people.
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of purchasing substances advertised as PCEs over the
internet (Forman et al. 2006a,b). As these drugs are not
prescribed by a qualiﬁed doctor, they might not
be suitable for some people. For instance, contra-
indications of atomoxetine and modaﬁnil include
heart problems and hepatic impairments (British
National Formulary, 2010). Additionally, if one is
taking other medication there might be serious
drug–drug interactions which could be dangerous in
some cases.
With regard to personal autonomy, there are ethical
concerns about healthy people being coerced or even
forced into using a PCE. Society might force people to
take psychoactive agents in order to perform better or
to be in a particular mental state. For example, auth-
orities in the USA ordered a mentally ill inmate in
criminal proceedings to take psychotropic medication
to improve his competence to stand trial and be exe-
cuted (Boire & Ruiz-Sierra, 2003; Randall, 2004). There
is also a considerable potential for indirect coercion
resulting from a highly demanding 24/7 society where
people feel compelled to take PCEs in order to meet
social or workplace demands. Healthy people may
resort to self-medication for inadequate sleep or over-
exertion at work. For example, 33% of respondents in
Maher’s (2008) poll indicated that they would feel
pressure to give PCE drugs to their children if other
children at school were taking them. However, the use
of PCEs to enhance cognition is one solution to im-
proving the individual and society. Indeed, we have
argued elsewhere that there are other methods of
boosting cognition, including education and exercise
(Sahakian & Morein-Zamir, 2010). For instance,
physical exercise can improve learning and memory
(Creer et al. 2010; Hillman et al. 2008). Through these
non-pharmacological means we might be able to ef-
fectively and safely enhance cognition and well-being
in society.
Another argument against their use is that they
might further exacerbate the ever-growing disparity
and inequality in society, especially if only the wealthy
can access them. Equally, is it morally justiﬁed to use
PCEs during exams, and does it give the user unfair
advantage over those who are equally capable but not
cognitively enhanced with drugs? Many universities
as yet have no formal policy about the use of PCEs
during exams. If PCEs become easily accessible in the
future, will society consider their use as cheating
or will they equate them to having a caﬀeine boost
from coﬀee? Is it possible that once PCE drugs are
widely available we might run the risk of becoming
a homogeneous society? Could our perception of
ourselves change from being human to being mech-
anistic beings with a modicum of emotion? Are we
going to be over-enhanced only to be plagued by un-
wanted memories? Will using PCEs outdate important
human virtues such as hard work and reﬂection and
make us unable to take credit for our minds’ achieve-
ments?
The advantages and disadvantages of using PCEs
have to be evaluated carefully. With regards to fair-
ness, enhancing cognition might lead to dramatic so-
cial beneﬁts by reducing natural inequality and
promoting social justice (Savulescu, 2006). This is be-
cause increasing cognitive ability on an individual
level could have dramatic and positive eﬀects on
society and the economy as a whole (Bostrom, 2008).
For instance, a 3% population-wide increase in IQ
would reduce poverty rates by 25% (Weiss, 1998), and
would lead to an annual economic gain of US$165–195
billion and up to 1.5% GDP growth (Salkever, 2005;
Schwartz, 1994).
Public engagement in neuroscience
However, if healthy people take PCEs to gain a
competitive edge but fail to see any diﬀerence in the
long-term or notice possible impairments observed in
high-functioning adults (Mattay et al. 2003) it could
spark controversy and outcry in the public. Hence,
determining who can use PCEs and under what cir-
cumstances involves complex decision making and
ethical judgements. Thus, how neuroscientiﬁc dis-
coveries impact on society has given rise to an
enormous interest in the ﬁeld of neuroethics, including
the foundation of the Neuroethics Society (http://
www.neuroethicssociety.org) which advocates further
research on ethical questions that are yet to be
answered. For instance, what are the possible long-
term harms of using PCE drugs in healthy people,
particularly in the developing brain? What are the
implications of developments in pharmacogenomics?
Without formal regulation of their use, healthy people
can purchase PCEs via the internet, with all the in-
herent dangers in doing so. How would such easy ac-
cess aﬀect widespread use of these drugs by healthy
young and elderly people and also impact on society?
How would we, as neuropsychopharmacologists, re-
act if we discover that our colleagues or our children’s
friends are taking PCEs? How should governments
react? These questions in neuropsychopharmacology
and neuroethics merit further rigorous research. They
also clearly indicate the need to engage in discussion
with the public about the social and ethical implica-
tions of the use of PCEs by healthy individuals
The ethics of elective psychopharmacology 565(Morein-Zamir & Sahakian, 2009; Ringach, 2009).
For this to happen, neuropsychopharmacologists
need to integrate experimental results within a
neuroethical framework. In order to do this, they
need to innovatively work together with social scien-
tists, philosophers, and ethicists (Morein-Zamir &
Sahakian, 2009; Sahakian & Morein-Zamir, 2009,
2010). This increases neuroscientists’ role and re-
sponsibility in society (Farah et al. 2004) and puts them
in a leading position to engage policy makers and a
broad group of stakeholders, including the general
public. This will ensure that technological advances in
neuroscience are put to maximal beneﬁt and minimal
harm.
Conclusions
PCEs have the potential to ameliorate cognitive dys-
function and to provide important clinical beneﬁts
for patients. Further development of more eﬀective
PCEs with fewer side-eﬀects, in addition to neuro-
protective agents for patients with neurodegenerative
diseases such as AD, is clearly worthy of pursuit.
Pharmacogenomics will make it possible to target in-
dividuals with safe and eﬀective drugs. PCEs can also
improve cognitive function such as memory and at-
tention in healthy individuals. However, their long-
term cognitive enhancing potential as well as their
side-eﬀects in healthy people needs to be rigorously
determined. Currently, the unprecedented rise of PCE
use among the healthy raises numerous ethical issues.
Scientists need to work together with social scientists,
philosophers, ethicists, policy makers, and teachers
to actively discuss the ethical consequences of PCE
usage. This will ensure maximal beneﬁt and minimal
harm in the advances in neuroscience. Finally, the use
of PCEs to enhance cognition is one solution to
improving the individual and society. However, this
does not preclude other means of enhancing cognition
such as education and exercise (Beddington et al. 2008;
Sahakian et al. 2010).
Note
Supplementary material accompanies this paper on
the Journal’s website (http://journals.cambridge.org/
pnp).
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